Pulmonx Corp (LUNG) — SEC Financial Statements & Analysis

Pulmonx Corp (LUNG) is a surgical & medical instruments & apparatus company, incorporated in DE. Pulmonx Corp trades on Nasdaq as: LUNG. Pulmonx Corp (LUNG)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Pulmonx Corp carries a market cap of $55.21M, a P/E ratio of -1.15x, a P/B ratio of 1.41x, a P/S ratio of 0.63x, an enterprise value of $36.64M, and an EV/EBITDA multiple of -0.79x. On profitability, it posts a gross margin of 77.06%, an operating margin of -52.96%, a net margin of -55.03%, a Return on Equity (ROE) of -88.87%, a Return on Assets (ROA) of -36.74%, and a Return on Invested Capital (ROIC) of -169.43%. Per share, it reports EPS of $-1.13, diluted EPS of $-1.13, free cash flow per share of $-0.72, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -3.43% year-over-year, net income growth of -15.50% year-over-year, and EPS growth of -19.55% year-over-year. On the balance sheet, it maintains a current ratio of 4.32x, a quick ratio of 3.35x, working capital of $67.73M, a debt-to-equity ratio of 1.93x, a debt ratio of 0.66, an interest coverage ratio of -12.29x, free cash flow of $-30.67M (TTM), and net debt of $-18.57M. Figures sourced from SEC EDGAR.

Market Cap

$55.21M

P/E TTM

-1.15x

EPS TTM

$-1.13

P/B TTM

1.41x

ROE TTM

-88.87%

ROA TTM

-36.74%

Debt To Equity

1.93x

Free Cash Flow TTM

$-30.67M

Net Revenue TTM Growth 1Y

-3.43%

Data as of 2026-06-30 · Source: SEC EDGAR